- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05406206
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
A Phase II Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Fruquintinib as Third-line Therapy for Patients With Unresectable Colorectal Cancer Liver Metastases
Study Overview
Status
Intervention / Treatment
Detailed Description
This will be a single-arm, open-label, phase II study. This study will be divided into 2 stages: dose exploration and dose expansion. In the dose exploration stage, "3+3 dose escalation" design will be applied to determined the maximum tolerated dose (MTD) of fruquintinib for next stage:
Cohort A: HAIC + fruquintinib 3mg QD, 3 weeks on/1 week off (3w/1w). Cohort B: HAIC + fruquintinib 4mg QD, 3w/1w. Cohort C: HAIC + fruquintinib 5mg QD, 3w/1w.
All subjects of this study will be permitted to continue therapy with only safety monitoring and assessments for progression, if the product is well tolerated and the subject has stable disease or better.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xu Zhu, Master
- Phone Number: +86-13501146178
- Email: drzhuxu@163.com
Study Contact Backup
- Name: Aiwei Feng, MD
- Phone Number: +86-18643411808
- Email: ivyfeng_1026@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Xu Zhu, Master
- Phone Number: 0086-10-88196330
- Email: drzhuxu@163.xom
-
Principal Investigator:
- Xu Zhu, Master
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years and ≤75, at the time of study entry.
- Histologically or cytologically documented advanced colorectal carcinoma with unresectable liver metastasis (existence of extrahepatic metastasis is acceptable).
- Previously received 2 lines of standard chemotherapy, including 5-FU, oxaliplatin, and irinotecan.
- Subjects must have at least one measurable lesion per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Estimated life expectancy of ≥12 weeks.
- Adequate organ functions verified by laboratory tests within 7 days before the first intervention, including bone marrow, liver and kidney function, and coagulation function
- Female subjects of childbearing potential who are sexually active with a nonsterilized male partner must use an acceptable method of contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product.
- Written and signed informed consent.
Exclusion Criteria:
- ANC<1.5×10*9/L, PLT<80×10*9/L, or Hb<9g/dL; no blood infusion within 2 weeks.
- TBil>2.5 × ULN.
- AST or ALT>5 × ULN.
- Serum Cr>1.5 × ULN, or CrCl<50 ml/min (calculated by Cockcroft-Gault equation)
- APTT or PT> 1.5 × ULN.
- Clinically significant electrolyte abnormalities determined by investigators.
- Proteinuria ≥ 2+ (1.0g/24hr).
- Hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg
- Active gastrointestinal ulceration, ulcerative colitis, or gastrointestinal bleeding; potential gastrointestinal bleeding or perforation determined by investigators.
- History of arterial thrombosis or deep venous thrombosis within 6 months before enrollment; evidence of hemorrhagic tendency or receiving anticoagulant therapy within 2 months before enrollment.
- Stroke or transient cerebral ischemia occurred within 12 months before enrollment.
- History of cardiovascular disease within 6 months before enrollment, including congestive heart failure (NYHA grade>2), acute myocardial ischemia, severe/unstable angina or CABG; or LVEF<50%.
- Uncontrollable malignant ascites, pleural effusion, or pericardial effusion (determined by investigators).
- Previous treated with VEGFR inhibitors.
- Other malignant tumors in the past 5 years, except skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ.
- Evidence of CNS metastasis.
- Active infection, such as acute pneumonia, active stage of HBV/HCV.
- Pregnant or lactating women.
- By judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study.
- Severe mental illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAIC combined with Fruquintinib
HAIC with fruquintinib until progression.
Fruquintinib should be administrated within 1 week after HAIC.
|
Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
Other Names:
HAIC is a locoregional therapy for colorectal cancer liver metastasis.
Oxaliplatin 85 mg/m*2 + 5-FU 2000 mg/m*2, Q4W
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Up to 2 years
|
Progression-free survival is defined as the time from the start of treatment HAIC until the first documentation of disease progression or death due to any cause, whichever occurs first.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to 2 years
|
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.
|
Up to 2 years
|
Duration of Response (DoR)
Time Frame: Up to 2 years
|
Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years
|
Overall survival is defined as the time from the start of treatment with HAIC until death due to any cause.
|
Up to 2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Liver Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasm Metastasis
- Liver Neoplasms
Other Study ID Numbers
- Fru-HAIC-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Metastasis Colon Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingColorectal Cancer | Colon Cancer | Liver Metastasis Colon Cancer | Adenocarcinoma of the Rectum | Colon Cancer Liver Metastasis | Adenocarcinoma of the ColonUnited States
-
McGill University Health Centre/Research Institute...RecruitingLiver Dysfunction | Liver Metastasis Colon Cancer | Liver RegenerationCanada
-
Lawson Health Research InstituteBayerRecruiting
-
AllVascularRecruitingLiver Metastasis Colon CancerAustralia
-
University of ManchesterManchester University NHS Foundation Trust; The Christie NHS Foundation Trust; Perspect... and other collaboratorsUnknownCancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Cancer MetastaticUnited Kingdom
-
First Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingLiver Metastasis Colon CancerChina
-
University of LeedsNational Cancer Institute (NCI); Massachusetts General Hospital; Massachusetts... and other collaboratorsRecruitingColon Cancer Liver MetastasisUnited Kingdom
-
Western University, CanadaNot yet recruitingNAFLD | Liver Metastasis Colon Cancer | Liver Steatoses
-
International Group of Endovascular OncologyCompletedObservational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab (TACETUX)Colon Cancer Liver MetastasisItaly
-
PerspectumActive, not recruitingLiver Cancer | Liver Metastasis Colon CancerUnited Kingdom
Clinical Trials on Fruquintinib
-
HutchmedRecruitingAdvanced Solid TumorChina
-
Hutchison Medipharma LimitedWithdrawn
-
Zhen-Yu DingCompleted
-
Hutchison Medipharma LimitedCompletedFood-drug Interaction | Drug InteractionUnited States
-
Fudan UniversityRecruiting
-
Shanghai Zhongshan HospitalRecruiting
-
Wuhan Union Hospital, ChinaNot yet recruiting
-
RenJi HospitalActive, not recruitingStomach NeoplasmsChina
-
Peking UniversityUnknown
-
Tianjin Medical University Cancer Institute and...Recruiting